On December 9, 2019, the European Commission published the Commission Implementing Regulation 2019/2094 of 29 November 2019 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mancozeb, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin.

The approval periods of these active substances is extended until January 31, 2021, or February 28, 2021, depending on the substances.
 
This regulation entered into force on December 29, 2019.